CA3242513A1 - Compositions and methods for reducing oxidation of igf?1/igfbp - Google Patents

Compositions and methods for reducing oxidation of igf?1/igfbp

Info

Publication number
CA3242513A1
CA3242513A1 CA3242513A CA3242513A CA3242513A1 CA 3242513 A1 CA3242513 A1 CA 3242513A1 CA 3242513 A CA3242513 A CA 3242513A CA 3242513 A CA3242513 A CA 3242513A CA 3242513 A1 CA3242513 A1 CA 3242513A1
Authority
CA
Canada
Prior art keywords
compositions
igfbp
igf
methods
reducing oxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242513A
Other languages
English (en)
French (fr)
Inventor
Nazila Salamat-Miller
Kris Lowe
Michael Hahn
Katherine Taylor
Original Assignee
Oak Hill Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oak Hill Bio Ltd filed Critical Oak Hill Bio Ltd
Publication of CA3242513A1 publication Critical patent/CA3242513A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3242513A 2022-01-19 2023-01-18 Compositions and methods for reducing oxidation of igf?1/igfbp Pending CA3242513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300860P 2022-01-19 2022-01-19
US63/300,860 2022-01-19
PCT/EP2023/051110 WO2023139115A1 (en) 2022-01-19 2023-01-18 Compositions and methods for reducing oxidation of igf‐1/igfbp

Publications (1)

Publication Number Publication Date
CA3242513A1 true CA3242513A1 (en) 2023-07-27

Family

ID=85036292

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242513A Pending CA3242513A1 (en) 2022-01-19 2023-01-18 Compositions and methods for reducing oxidation of igf?1/igfbp

Country Status (10)

Country Link
US (1) US20250099541A1 (enExample)
EP (1) EP4466281A1 (enExample)
JP (1) JP2025502349A (enExample)
KR (1) KR20240136382A (enExample)
CN (1) CN118574840A (enExample)
AU (1) AU2023210427A1 (enExample)
CA (1) CA3242513A1 (enExample)
IL (1) IL314331A (enExample)
MX (1) MX2024008819A (enExample)
WO (1) WO2023139115A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005966T3 (en) * 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
ES3005966T3 (en) 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates

Also Published As

Publication number Publication date
EP4466281A1 (en) 2024-11-27
JP2025502349A (ja) 2025-01-24
CN118574840A (zh) 2024-08-30
MX2024008819A (es) 2024-09-17
AU2023210427A1 (en) 2024-08-22
WO2023139115A1 (en) 2023-07-27
AU2023210427A2 (en) 2025-01-09
KR20240136382A (ko) 2024-09-13
IL314331A (en) 2024-09-01
US20250099541A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
De Mellow et al. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts
CA1181343A (en) Sterilized, preserved, stable mucine-containing solutions and methods for their preparation
KR910002667B1 (ko) 2-효소성 치약
Einspanier et al. Bovine seminal plasma aSFP: localization of disulfide bridges and detection of three different isoelectric forms
US5696078A (en) Methods of treating fungal infections using histatin-based peptides
Calvete et al. The primary structure of BSP‐30K, a major lipid‐, gelatin‐, and heparin‐binding glycoprotein of bovine seminal plasma
Strawich et al. Tooth ‘enamelins’ identified mainly as serum proteins: major ‘enamelin’is albumin
DenBesten et al. Enamel proteases in secretory and maturation enamel of rats ingesting 0 and 100 PPM fluoride in drinking water
CA2254145A1 (en) Improved process to stabilize proteins
CA2469498A1 (en) Stable oral compositions comprising casein phosphopeptide complexes and fluoride
Månsson-Rahemtulla et al. Analyses of salivary components in leukemia patients receiving chemotherapy
St. Angelo et al. Effects of lipoperoxides on proteins in raw and processed peanuts
WO2003013487A3 (en) Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
WO2002102360A3 (en) Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes
DE69728163D1 (de) Zusammensetzung aus aminosäuren
EP0446315A4 (en) Recombinant product
Bhattacharyya et al. Isolation and characterization of a pulmonary glycoprotein from human amniotic fluid
Hess et al. The amino acid composition of proteins isolated from the healthy enamel and dentin of carious teeth
Yu et al. Isolation of a heme binding subunit from bovine heart cytochrome c oxidase
Lejeune et al. Amino acid sequence around a hormonogenic tyrosine residue in the N-terminal region of human thyroglobulin after in vivo and in vitro iodination
Yoshizaki et al. Purification, crystallization, and properties of plastocyanin from a green alga, Enteromorpha prolifera
MX2024008819A (es) Composiciones y metodos para reducir la oxidacion de igf-1/igfbp.
Manson et al. Formation of lysinoalanine from individual bovine caseins
Mori et al. Physicochemical characterization of native and asialo human chorionic gonadotropin
JPS57171909A (en) Composition for oral cavity

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250109

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250109

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260108